BackCan-Fite BioPharma Overview

Can-Fite BioPharma Current Cash

Track Can-Fite BioPharma's current cash ($3M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$2.98M
↓ 53.75% YoYΔ $-3.47M vs prior year quarter

Peer trimmed avg / median

Loading

Can-Fite BioPharma Current Cash History

Loading

Can-Fite BioPharma vs. peers: Current Cash Comparison

Loading

Can-Fite BioPharma Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Can-Fite BioPharma (CANF.TA) FAQ

Can-Fite BioPharma's current cash stands at $3M as of June 2026. That compares with $6.5M in the prior-year period — down 53.7% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Can-Fite BioPharma reported $3M in current cash versus $6.5M a year earlier — a 53.7% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $6.5M in the prior-year period — down 53.7% year over year. Sustained growth in current cash can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Can-Fite BioPharma's current cash evolved across reporting periods, while the comparison chart places CANF.TA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, current cash is commonly used to spot outliers. Can-Fite BioPharma's reading of $3M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.